Last updated: May 30, 2026
GLYBURIDE and METFORMIN HYDROCHLORIDE Suppliers: API, Intermediates, and Contract Manufacturing
GLYBURIDE and METFORMIN HYDROCHLORIDE are supplied globally through a multi-tier ecosystem spanning API producers, intermediate makers, and contract manufacturing organizations (CMOs) that formulate tablets and extended-release (where applicable). Supplier qualification for these actives typically hinges on DMF/ASMF status, regulatory inspection history, particle-size control for metformin grades, and validated crystallization/formulation processes for glyburide solid-state forms.
Which companies supply GLYBURIDE API and intermediates?
The glyburide supply chain is dominated by Asian API manufacturers and European specialty suppliers for certain grades and particle-size specifications. Business-critical supplier-screening usually checks: (1) DMF/ASMF listing, (2) EU CEPs or relevant European controls, (3) CEP availability for excipient systems used in tablets, (4) API batch consistency for solid form and dissolution profile, and (5) ability to support scale-ups under cGMP.
What glyburide API grades and solid-state controls matter for buyers?
For glyburide tablets, buyers typically require:
- Solid-form consistency (polymorph/solvate control is a common technical gating item)
- Dissolution and bioequivalence-relevant specifications
- Particle size distribution that supports uniformity of dose blending and tableting
What intermediates are commonly sourced for glyburide?
Glyburide manufacturing generally relies on benzimidazole/benzyl intermediates formed through multi-step heterocycle synthesis, followed by sulfamide and cyclization steps (route varies by producer). Procurement diligence usually focuses on impurity profiles, genotoxic impurity controls, and scalability of the late-stage cyclization step.
Which companies supply METFORMIN HYDROCHLORIDE API?
Metformin hydrochloride has a deeper, more liquid global supplier base than glyburide. API availability is broad, and supplier differentiation is usually driven by:
- Salt-grade specifications (metformin HCl purity and controlled water content)
- Particle size distribution and bulk density for direct compression suitability
- Consistent impurity profiles, especially related to N,N-dimethylamine-derived impurities
- Ability to provide suitable grades for immediate-release and extended-release formulations
Do metformin suppliers offer different grades for IR vs ER?
Yes. Buyers often separate supplier qualification for:
- Immediate-release (IR) metformin HCl tablets
- Extended-release (ER) metformin HCl tablets (requires additional downstream controls during polymer matrix formation, even when API is the same active)
- High-throughput grades optimized for blending and roller compaction
What suppliers support fixed-dose combinations of GLYBURIDE + METFORMIN HYDROCHLORIDE?
Fixed-dose combinations (FDCs) require coordinated supply of both APIs plus a formulation system that controls:
- Content uniformity across both actives
- Dissolution profile synchronization for glyburide
- Compatibility between metformin HCl and formulation excipients under accelerated stability
- Robust manufacturing controls for tablet hardness and friability
In practice, supply options split into:
- API suppliers that also run contract formulation/packaging.
- Pure API suppliers paired with an independent CMO experienced in antidiabetic FDC tablet lines.
- CMOs that source APIs through buyer-approved channels.
What contract manufacturing organizations (CMOs) can produce tablets for these drugs?
CMO eligibility is usually established through:
- cGMP record and inspection history for oral solid dosage forms
- validated compression and blending capability for glyburide (fine particle and dissolution-sensitive)
- metformin-specific process capability (including moisture control and impurity control)
- full documentation support (batch records, CoA structure, stability protocol execution)
CMO selection for antidiabetic tablets is typically constrained by line clearance procedures, cross-product contamination controls, and ability to handle both IR tablet manufacturing and, where relevant, ER coating or matrix operations.
How do buyers qualify GLYBURIDE and METFORMIN suppliers in the US and EU?
Regulatory qualification hinges on whether the buyer intends to reference:
- a Drug Master File (DMF) for API, or
- an Active Substance Master File (ASMF) in the EU framework (common for European submissions)
What documentation is typically required from API suppliers?
Common procurement requirements include:
- CoA with full-spec impurity list and residual solvents
- GMP certificate for the specific manufacturing site
- DMF/ASMF holder or letter of access structure
- Stability data package for intended shelf life
- Change control notification process and comparability protocols
What impurity and genotoxic impurity controls are most scrutinized?
For both actives, buyers typically request:
- Impurity profile trending
- Identification thresholds and qualification for impurities from route variations
- Genotoxic impurity controls aligned with current ICH expectations
What is the Orange Book or exclusivity status relevance for supplier planning?
For supplier planning, exclusivity and listing status dictate whether originator supply can be underwritten via licensing or whether generic manufacturing can proceed without IP risk. Supplier contracts for the actives themselves do not erase the need to assess:
- drug product patents and formulation patents (for the final marketed strength and dosage form)
- method-of-use protections tied to specific regimens
- any product-specific exclusivity and Paragraph IV litigation history involving the FDC
Because exclusivity and listing status are product-specific (brand and dosage form), supplier negotiations for FDCs typically include an IP indemnity or a product-level risk review tied to the target NDA/ANDA label.
Which sourcing routes are lower risk: direct API buy vs supplier-managed formulation?
In procurement practice:
- Direct API purchasing is lower cost but increases integration burden on the finished-dose CMO and raises technical risk during scale-up.
- Supplier-managed formulation (where the API supplier also runs the tablet manufacturing) reduces integration risk but concentrates dependency on a single vendor for both actives and process.
What commercial and operational factors affect pricing and availability for these drugs?
Key drivers include:
- API capacity utilization and regional supply concentration
- Solid-state control costs for glyburide and grade requirements for metformin HCl
- Freight volatility and longer lead times for some intermediate routes
- Regulatory inspection outcomes for manufacturing sites
- DMF/ASMF approvals timing and change control cadence
Supplier selection checklist for GLYBURIDE and METFORMIN HYDROCHLORIDE tablets
Use a qualification package that tests:
- cGMP compliance for each API manufacturing site
- DMF/ASMF status with letter of access
- impurity control and residual solvent compliance
- solid-form and dissolution alignment for glyburide
- metformin bulk density and particle-size spec performance for blending
- stability and packaging compatibility for the intended tablet strengths
- change control SLA and right-to-audit terms
Key Takeaways
- Glyburide and metformin hydrochloride draw from mature global API supply networks, with supplier differentiation driven by solid-state and impurity control.
- For FDC tablets, the binding constraint is less “API availability” and more “process integration” across both actives in a tablet system that meets dissolution and content-uniformity specs.
- Supplier qualification in regulatory markets is typically DMF/ASMF and GMP-site specific, with impurity packages and change control as gating items.
FAQs
1. What should an API buyer verify on a metformin HCl supplier’s CoA?
Purity spec, total and individual impurities, residual solvents, moisture control, and particle-size/bulk density values tied to the buyer’s manufacturing process.
2. How does glyburide solid-state variability affect tablet performance?
It can shift dissolution behavior and tablet-to-tablet variability, so buyers validate solid form and dissolution targets during tech transfer.
3. What are the typical risks in outsourcing GLYBURIDE + METFORMIN FDC tablet manufacturing?
Process integration risk (blending, compression, dissolution alignment), moisture/compatibility stability risk, and regulatory documentation completeness for DMF/ASMF references.
4. Do metformin and glyburide suppliers usually support both IR and ER manufacture?
Metformin suppliers can support grades suitable for ER, but formulation capability and manufacturing controls for ER are usually CMO- or product-specific.
5. What supplier documentation is most important for DMF/ASMF-driven submissions?
Letter of access, complete impurity profiles, stability packages, and site-specific GMP alignment tied to the intended regulatory filing route.
References
None provided in the prompt.
